Cargando...
HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience
Erythropoiesis-stimulating agents, such as recombinant human erythropoietin, are commonly used for the treatment of anemia in patients with chronic kidney disease (CKD). In 2007, HX575 (Binocrit(®)) became the first biosimilar epoetin alfa to be approved by the European Medicines Agency (EMA). The d...
Gardado en:
| Publicado en: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5739117/ https://ncbi.nlm.nih.gov/pubmed/29296077 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S146147 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|